Cargando…
Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients
Therapy-related acute lymphoblastic leukemia remains poorly defined due to a lack of large data sets recognizing the defining characteristics of this entity. We reviewed all consecutive cases of adult acute lymphoblastic leukemia treated at our institution between 2000 and 2017 and identified therap...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165794/ https://www.ncbi.nlm.nih.gov/pubmed/29903756 http://dx.doi.org/10.3324/haematol.2018.193599 |
_version_ | 1783359908345806848 |
---|---|
author | Aldoss, Ibrahim Stiller, Tracey Tsai, Ni-Chun Song, Joo Y. Cao, Thai Bandara, N. Achini Salhotra, Amandeep Khaled, Samer Aribi, Ahmed Al Malki, Monzr M. Mei, Matthew Ali, Haris Spielberger, Ricardo O’Donnell, Margaret Snyder, David Slavin, Thomas Nakamura, Ryotaro Stein, Anthony S. Forman, Stephen J. Marcucci, Guido Pullarkat, Vinod |
author_facet | Aldoss, Ibrahim Stiller, Tracey Tsai, Ni-Chun Song, Joo Y. Cao, Thai Bandara, N. Achini Salhotra, Amandeep Khaled, Samer Aribi, Ahmed Al Malki, Monzr M. Mei, Matthew Ali, Haris Spielberger, Ricardo O’Donnell, Margaret Snyder, David Slavin, Thomas Nakamura, Ryotaro Stein, Anthony S. Forman, Stephen J. Marcucci, Guido Pullarkat, Vinod |
author_sort | Aldoss, Ibrahim |
collection | PubMed |
description | Therapy-related acute lymphoblastic leukemia remains poorly defined due to a lack of large data sets recognizing the defining characteristics of this entity. We reviewed all consecutive cases of adult acute lymphoblastic leukemia treated at our institution between 2000 and 2017 and identified therapy-related cases - defined as acute lymphoblastic leukemia preceded by prior exposure to cytotoxic chemotherapy and/or radiation. Of 1022 patients with acute lymphoblastic leukemia, 93 (9.1%) were classified as therapy-related. The median latency for therapy-related acute lymphoblastic leukemia onset was 6.8 years from original diagnosis, and this was shorter for patients carrying the MLL gene rearrangement compared to those with other cytogenetics. When compared to de novo acute lymphoblastic leukemia, therapy-related patients were older (P<0.01), more often female (P<0.01), and had more MLL gene rearrangement (P<0.0001) and chromosomes 5/7 aberrations (P=0.02). Although therapy-related acute lymphoblastic leukemia was associated with inferior 2-year overall survival compared to de novo cases (46.0% vs. 68.1%, P=0.001), prior exposure to cytotoxic therapy (therapy-related) did not independently impact survival in multivariate analysis (HR=1.32; 95% CI: 0.97–1.80, P=0.08). There was no survival difference (2-year = 53.4% vs. 58.9%, P=0.68) between the two groups in patients who received allogenic hematopoietic cell transplantation. In conclusion, therapy-related acute lymphoblastic leukemia represents a significant proportion of adult acute lymphoblastic leukemia diagnoses, and a subset of cases carry clinical and cytogenetic abnormalities similar to therapy-related myeloid neoplasms. Although survival of therapy-related acute lymphoblastic leukemia was inferior to de novo cases, allogeneic hematopoietic cell transplantation outcomes were comparable for the two entities. |
format | Online Article Text |
id | pubmed-6165794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Ferrata Storti Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-61657942018-10-04 Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients Aldoss, Ibrahim Stiller, Tracey Tsai, Ni-Chun Song, Joo Y. Cao, Thai Bandara, N. Achini Salhotra, Amandeep Khaled, Samer Aribi, Ahmed Al Malki, Monzr M. Mei, Matthew Ali, Haris Spielberger, Ricardo O’Donnell, Margaret Snyder, David Slavin, Thomas Nakamura, Ryotaro Stein, Anthony S. Forman, Stephen J. Marcucci, Guido Pullarkat, Vinod Haematologica Article Therapy-related acute lymphoblastic leukemia remains poorly defined due to a lack of large data sets recognizing the defining characteristics of this entity. We reviewed all consecutive cases of adult acute lymphoblastic leukemia treated at our institution between 2000 and 2017 and identified therapy-related cases - defined as acute lymphoblastic leukemia preceded by prior exposure to cytotoxic chemotherapy and/or radiation. Of 1022 patients with acute lymphoblastic leukemia, 93 (9.1%) were classified as therapy-related. The median latency for therapy-related acute lymphoblastic leukemia onset was 6.8 years from original diagnosis, and this was shorter for patients carrying the MLL gene rearrangement compared to those with other cytogenetics. When compared to de novo acute lymphoblastic leukemia, therapy-related patients were older (P<0.01), more often female (P<0.01), and had more MLL gene rearrangement (P<0.0001) and chromosomes 5/7 aberrations (P=0.02). Although therapy-related acute lymphoblastic leukemia was associated with inferior 2-year overall survival compared to de novo cases (46.0% vs. 68.1%, P=0.001), prior exposure to cytotoxic therapy (therapy-related) did not independently impact survival in multivariate analysis (HR=1.32; 95% CI: 0.97–1.80, P=0.08). There was no survival difference (2-year = 53.4% vs. 58.9%, P=0.68) between the two groups in patients who received allogenic hematopoietic cell transplantation. In conclusion, therapy-related acute lymphoblastic leukemia represents a significant proportion of adult acute lymphoblastic leukemia diagnoses, and a subset of cases carry clinical and cytogenetic abnormalities similar to therapy-related myeloid neoplasms. Although survival of therapy-related acute lymphoblastic leukemia was inferior to de novo cases, allogeneic hematopoietic cell transplantation outcomes were comparable for the two entities. Ferrata Storti Foundation 2018-10 /pmc/articles/PMC6165794/ /pubmed/29903756 http://dx.doi.org/10.3324/haematol.2018.193599 Text en Copyright © 2018 Ferrata Storti Foundation Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher. |
spellingShingle | Article Aldoss, Ibrahim Stiller, Tracey Tsai, Ni-Chun Song, Joo Y. Cao, Thai Bandara, N. Achini Salhotra, Amandeep Khaled, Samer Aribi, Ahmed Al Malki, Monzr M. Mei, Matthew Ali, Haris Spielberger, Ricardo O’Donnell, Margaret Snyder, David Slavin, Thomas Nakamura, Ryotaro Stein, Anthony S. Forman, Stephen J. Marcucci, Guido Pullarkat, Vinod Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients |
title | Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients |
title_full | Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients |
title_fullStr | Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients |
title_full_unstemmed | Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients |
title_short | Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients |
title_sort | therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165794/ https://www.ncbi.nlm.nih.gov/pubmed/29903756 http://dx.doi.org/10.3324/haematol.2018.193599 |
work_keys_str_mv | AT aldossibrahim therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT stillertracey therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT tsainichun therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT songjooy therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT caothai therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT bandaranachini therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT salhotraamandeep therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT khaledsamer therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT aribiahmed therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT almalkimonzrm therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT meimatthew therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT aliharis therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT spielbergerricardo therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT odonnellmargaret therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT snyderdavid therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT slavinthomas therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT nakamuraryotaro therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT steinanthonys therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT formanstephenj therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT marcucciguido therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients AT pullarkatvinod therapyrelatedacutelymphoblasticleukemiahasdistinctclinicalandcytogeneticfeaturescomparedtodenovoacutelymphoblasticleukemiabutoutcomesarecomparableintransplantedpatients |